

2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Inning One Ventures II | April 2024 | $36M | $36M | 39 |
| Inning One Ventures | September 2018 | $50M | $10M | 4 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Haider Akmal | Quiet | None listed | 1 | 0 |
| Martin Vogelbaum | Quiet | Biotech & pharma | 3 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Too few companies classified yet to infer a focus. 1 of 4 portfolio companies are classified.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Inning One Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| TCG Crossover | 1 | Nora Therapeutics |
| Third Rock Ventures | 1 | Nora Therapeutics |
| Vivo Capital | 1 | Nora Therapeutics |
A shared board seat: a company where filings name a Inning One Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.